Meclizine
Meclizine, antihistamine and motion sickness drug
Written by Aaron CuhaReviewed Sep 2026
Also known as: Meclozine, Antivert, Bonine, Dramamine Less Drowsy
An over-the-counter travel sickness pill that extended male mouse lifespan in one cohort, and did nothing when the same programme retested it at a different dose.
Overview
Meclizine is the drug people buy for travel sickness, and it is on this site because the National Institute on Aging tested it for lifespan and it worked, once.
In the 2024 cohort it extended lifespan in male mice started at 12 months of age, with 90th percentile lifespan extended by 6 percent in absolute terms, not significant on the formal maximal lifespan test. Late-life weights were lower in treated females without a lifespan effect in them.
In the 2026 cohort, retested at a different dose or later starting age, it showed no benefit.
The reason anyone tested an antihistamine for ageing is more interesting than the drug: meclizine was found to shift cells away from oxidative phosphorylation toward glycolysis, which is the metabolic direction associated with protection against ischaemic injury. That is a genuine mechanistic rationale rather than a screening accident.
Mechanism of action
A first-generation H1 antihistamine with anticholinergic activity, which is how it works for motion sickness, by damping vestibular signalling. Its ageing rationale is unrelated: it was identified as shifting cellular metabolism away from oxidative phosphorylation toward glycolysis, apparently by interfering with the Kennedy pathway of phosphatidylethanolamine synthesis, which reduces mitochondrial respiration. That metabolic shift is protective in models of ischaemic injury, and the hypothesis was that a similar shift might reduce oxidative damage over a lifetime.
Human evidence
A long record as an over-the-counter antihistamine for motion sickness and vertigo. Nothing at all on ageing.
- Approved and widely used for motion sickness and vertigo, with a well-characterised safety profile at those doses.
- Sedation and anticholinergic effects including dry mouth and, in older people, confusion are the usual adverse effects.
- Anticholinergic burden is a recognised concern in older adults, which matters because that is the population any ageing use would target.
- No human study has examined lifespan, healthspan or any geroscience endpoint.
What this does not tell you: Two mouse cohorts that disagree constitute the entire ageing case. The anticholinergic point deserves weight: cumulative anticholinergic exposure in older adults is associated with cognitive harm, so the population in which an ageing benefit would matter is the population in which this drug class is most problematic. That is a poor risk profile against a mouse result that did not replicate.
Reading the research record
The 2026 cohort did something unusual and valuable: it retested compounds the same programme had already found to extend lifespan, at different doses or from later starting ages. Astaxanthin, mitoglitazone and meclizine all showed no benefit the second time. In females, pooling all three sites, astaxanthin, late-start mitoglitazone and pioglitazone were associated with significantly reduced lifespan; a site-specific reanalysis found unusually long-lived control females at one site, and excluding it left the negative effect for mitoglitazone and pioglitazone only. The authors' own conclusion is that timing and dosage are critical variables and that single-site or single-cohort findings require cautious interpretation.
Meclizine is also a useful counterweight to the assumption that repurposing an old cheap drug is a shortcut. The rationale here was good: a specific, published metabolic mechanism shifting cells away from oxidative phosphorylation, with a plausible link to reduced lifetime oxidative damage. The first result supported it in male mice. The retest did not.
And the drug's own pharmacology works against the use case. It is an anticholinergic, and cumulative anticholinergic burden in older adults is associated with cognitive harm, so the group most likely to want a longevity drug is the group least suited to this one.
The Interventions Testing Program is run by the National Institute on Aging at three independent sites, using UM-HET3 mice, a genetically heterogeneous four-way cross, so a result cannot be an artefact of one inbred strain. Both sexes are tested, cohorts are large enough to detect roughly a 10 percent change in lifespan, and nulls are published alongside positives. Nothing else in ageing research has that combination, which is why its results carry more weight than a single-laboratory finding and why its failures to replicate are worth as much attention as its successes.
The evidence, charted
Fig. 1 · evidence composition
0of 2 citations (0%) are in people
Every citation cited here is Animal work; no other study type is cited on this page. This count is of our own citation list and understates any literature larger than the sources we cite.
Fig. 2 · evidence over time
Citations here span just two years, 2024 and 2026.
Too few distinct publication years on this page to plot as a timeline.
Fig. 3 · legal status at a glance
US
Prescription
UK
Approved
AU
Approved
CA
Approved
Approved in 3 of 4, prescription route in 1, not approved in 0. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Animal2024
Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002, dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not
Interventions Testing Program. Meclizine, fed at 544 plus or minus 48 ppm and started at 12 months of age, extended lifespan in male mice. The 90th percentile lifespan was extended in absolute value by 6 percent in males but not significantly by the Wang-Allison test. Late-life weights were lower in treated females without a significant lifespan effect in them.
GeroScience - Animal2026
Astaxanthin, meclizine, mitoglitazone, pioglitazone, alpha-ketoglutarate, mifepristone, methotrexate, and atorvastatin-telmisartan do not increase lifespan
The retest. Meclizine showed no lifespan benefit at a different dose or a later starting age. One of eleven compounds in that cohort, none of which increased lifespan in either sex.
GeroScience
Frequently asked questions
Can a travel sickness pill extend lifespan?
It extended male mouse lifespan in one cohort of the National Institute on Aging's testing programme and produced nothing when the same programme retested it at a different dose or a later starting age. There is no human ageing data.
Why would an antihistamine affect ageing?
Not through the antihistamine action. Meclizine was found to shift cellular metabolism away from oxidative phosphorylation toward glycolysis, a state that is protective against ischaemic injury, and the hypothesis was that the same shift might reduce oxidative damage across a lifetime. A real mechanistic rationale rather than a screening accident.
Should older adults take it for longevity?
Specifically not. It is anticholinergic, and cumulative anticholinergic burden in older adults is linked to cognitive harm. The people a longevity drug would target are the people this drug class is worst for, and the mouse result did not replicate.